Moreover, in CRC patients, SEPT9 promoter methylation levels were significantly higher in patients with stage IV or distant metastatic disease (M1) (p < 0.01, in all comparisons) (Figure 2(B2)). The gene discussed is SEPTIN9; the disease is metastatic neoplasm.